In the present report we have determined the molecular mechanisms, which govern the expression of the human IL-10 gene when induced by the 
Role of Stat3 in Glucocorticoid-induced Expression of the human IL-10 Gene
Introduction IL-10 is a major immunosuppressive cytokine produced by T-cells, monocytes / macrophages, dendritic cells and B-cells (Chang et al., 2000; de Waal Malefyt et al., 1992; Fiorentino et al., 1989) . IL-10 will suppress the immune response by decreasing cell surface expression of MHC class II and by down-regulating the expression of cytokines like Tumour Necrosis Factor (de Waal Malefyt et al., 1991) .
The immunosuppressive activity of IL-10 becomes obvious when looking at IL-10 knock-out mice, which show spontaneous autoimmune disease and increased resistance to infection (Bettelli et al., 1998; Dai et al., 1997) .
Changes in the expression of IL-10 upon activation of leukocytes are mainly transcriptional and several factors have been implicated in its control. For the murine IL-10 gene Sp1 was reported to have an important role in regulating LPSstimulated promoter activity (Brightbill et al., 2000) . The respective motif is promoter proximal and its mutation reduced both the inducible and the constitutive promoter activity in the murine RAW 264 macrophage cell line (Brightbill et al., 2000; Tone et al., 2000) . Ma et al. (Ma et al., 2001 ) noted an Sp1 site at -636 bp of the human promoter, which appeared to be responsible for all the inducible activity in monoblastic cells. For the human gene transactivation by catecholamines appears to require the action of C/EBP (Brenner et al., 2003) with the most important motif 44 bp downstream of the TATA box. Furthermore, there is evidence for a role of c-Maf in IL-10 gene expression, but demonstration of c-Maf binding to a -196 bp motif in the human IL-10 promoter requires overexpression of this transcription factor (Cao et al., 2002; Cao et al., 2005) .
Based on deletion and linker scanning analysis we have identified a STAT-motif at -120 that is crucial to gene expression in a human B cell line when stimulated with LPS (Benkhart et al., 2000) . Also, this motif was shown to be essential together with an up-stream IRF site for IFNα-induced IL-10 expression (ZieglerHeitbrock et al., 2003) . The role of STAT3 in expression of IL-10 has been confirmed in other cell types and in knock-out mice (Cheng et al., 2003; Herbeuval et al., 2004; Maritano et al., 2004) . Recently it was shown that SOCS3 deficiency in murine TCR-stimulated T cells led to increased STAT3 activity and IL-10 expression (Kinjyo et al., 2006) and that constitutive IL-10 expression in T cell lines can be blocked by depletion of STAT3 by RNA interference (Kasprzycka et al., 2006) . Hence it appears that the STAT-motif in the human IL-10 gene may be a central cis-element in regulation of this gene.
Glucocorticoids (GCs) are steroid hormones, which can potently suppress immune response and inflammation. Their main mode of action is via the glucocorticoid receptor-alpha (GCR-alpha), which is present in the cytosol as a homodimer, where it is bound to heat-shock proteins. When the lipophilic glucocorticoids enter the cell they bind to the receptor, leading to dissociation of the heat-shock proteins and to the translocation of the GCR into the nucleus. Here the GC-GCR complex will induce gene expression by binding to cognate DNA sequences (AGAACAnnnTGTTCT) (Smoak and Cidlowski, 2004) . On the other hand GC will act by binding to and interfering with the action of other transcription factors like NF-kB (Rhen and Cidlowski, 2005) , which will lead to suppression of genes like the pro-inflammatory Tumor Necrosis Factor.
Among the genes induced by glucocorticoids is the anti-inflammatory cytokine IL-10 and induction of this gene obviously will contribute to the antiinflammatory action of GCs. GC therapy has been shown to induce IL-10 in serum (Dandona et al., 1999) and in mononuclear cells (Gayo et al., 1998) . In addition, John et al demonstrated that in the BAL (bronchoalveolar lavage) of patients, treated with inhaled glucocorticoids, alveolar macrophages are the main producers of induced IL-10 (John et al., 1998) . According to in-vitro studies GC can induce IL-10 in monocytes (Mozo et al., 2004) and macrophages (Frankenberger et al., 2005) . Furthermore, GC treatment will induce IL-10 in T cells in therapeutic settings (Karagiannidis et al., 2004) and in in-vitro culture (Barrat et al., 2002; Richards et al., 2000) .
The molecular mechanism involved in glucocorticoid mediated induction of IL-10 has, however, not been determined to date. In the present report we demonstrate GC-induction of IL-10 in primary human B cells and in a B cell line. Analysis in this system of the cis-and trans-elements that control the human IL-10 promoter in GC-treated cells demonstrates that GCs act by inducing binding of the transcription factor STAT3 to the -120 motif in the human IL-10 gene. While induction of gene expression by GCs typically involves binding of the glucocorticoid receptor to a cognate glucocorticoid response element, our study describes a novel mode of action of GCs via direct activation of STAT3.
Experimental

Cell Culture
The human RPMI 8226.1 B cell line (Ziegler-Heitbrock et al., 1994) 
Isolation of peripheral blood mononuclear cells (PBMC)
PBMC were isolated from heparinised (10 U/mL) blood from healthy human volunteers by density gradient centrifugation (Lymphoprep, 1,077 g/mL, Oslo, Norway). All subjects gave written informed consent, and the Ethics Committee of the medical Faculty of Ludwig Maximilian University, Munich, approved the study. Cells were directly used for subsequent isolation of CD19+ B cells.
Isolation of primary CD19+ B Cells
For positive selection of CD19+ B cells, the MACS magnetic separation technique was used (all columns and reagents from Miltenyi Biotec, BergischGladbach, Germany). A total of 15 x 10 6 PBMC were resuspended in 80 µL of PBS containing 20 µL anti CD19-MicroBeads (130-050-301, Miltenyi Biotec).
After incubation for 30 min at 4°C, cells were washed and resuspended in 1,5 mL PBS and then loaded onto a LS column (#120-000-475) in a midiMACS magnet.
The column was washed five times with 2 mL PBS each. Cells were recovered from the column by flushing the column five times with 2 mL PBS using a plunger. CD19+ cells were washed and resuspended in RPMI 1640 Medium in a final concentration of 1x 10 6 cells/mL for stimulation. To determine purity of the CD19+ B cells, a sample was stained with FITC conjugated anti-CD19 antibody (#555412, Becton-Dickinson, Heidelberg, Germany) and measured by flow cytometry. CD19+ B cells with a purity of 95 % or higher were used.
Reporter plasmids, transfection and luciferase assay
In this project we employed a variety of luciferase reporter plasmids with wild type and mutant sequences of the human IL-10 promoter upstream of the luciferase reporter gene. The following constructs were used: In addition we used a linker scanning series based on pIL-10 (-150).luci, which has decameric parts of the -150 promoter sequence sequentially replaced by an inert sequence. These constructs are labelled pIL-10 LS1.luci through pIL-10 LS9.luci.
Construct name
All these constructs are described in Benkhart et al. (Benkhart et al., 2000; Ziegler-Heitbrock et al., 2003) . The RPMI 8226.1 cells were transfected according to the method described by Shakov et al. (Shakhov et al., 1990) . In brief, 1 x 10 7 cells in 1 mL RPMI 1640 Medium, supplemented with 2 mM LGlutamin (#25030-024, Invitrogen, Karlsruhe, Germany) and 66,6 µg/mL DEAE-Dextran (#E1210, Promega, Mannheim) were cotransfected with one of the promoter luciferase reporter constructs (mentioned above) and Renilla luciferase (#E6291, phRG-TK Vector; Promega, Mannheim) as internal control and incubated for 90 minutes at 37°C. After addition of 10 % DMSO for 150 s, cells were washed and cultured for 3 days in 6 well plates.
Cells were stimulated for 6 h with and without 6α-Methyl-Prednisolone at 10 -6 M.
Cell lysates were prepared using the Dual-Luciferase ® Reporter Assay System (#E1910, Promega, Mannheim) according to the manufacturer`s instructions.
Luciferase activity was measured in a Luminometer (Berthold, Pforzheim) and expressed as RLU/5x10E5 cells relative to Renilla.
Adenoviral (AdV) vectors and viral infections
A recombinant replication-deficient AdV vector encoding the STAT3 Tyr 705 → Phe mutation which is dominant negative (S3 DN) (Kunisada et al., 1998) was kindly provided by Y. Fasjio (Osaka University, Osaka, Japan). An identical construct, lacking the insert (AdV0), was provided by A. Byrnes and M. Wood (University of Oxford, Oxford, UK). The recombinant viruses were purified and concentrated as previously described (Foxwell et al., 1998) . RPMI-8226.1 cells were infected with virus in 24-well ultra low attachment plates (#3473, Costar) at a multiplicity of infection (MOI) of 50 for 2 h in serum-free media. FCS was then added to cultures and cells were incubated at standard conditions overnight. Cells were washed and re-suspended in media containing 10 % serum. Cells were then plated with 1 mL volumes /well on a 24 well ultra low attachment plate followed by stimulation.
Gel shift Analysis
Nuclear extracts were isolated according to the method described by Dignam et al. (Dignam et al., 1983) in the presence of a protease inhibitor mixture ( Gels were run with a distance of 10 cm for standard gelshift and 15 cm for supershift analysis.
Chromatin Immunoprecipitation
For ChIP 2x10 7 cells were stimulated with and without 6α-Methyl-Prednisolone (MP) at 10 -6 M for 2 h. Cells were cross-linked in 1 % formaldehyde for 30 min.
Cross-linking was stopped by the addition of glycine to a final concentration of 1.25 M. Cells were washed with ice cold PBS, Buffer B (0,25 % Triton X-100, 10 mM EDTA pH 8, 0,5 mM EGTA pH 8, 20 mM HEPES pH 7,6) and Buffer C (0,15 M NaCl, 1 mM EDTA pH 8, 0,5 mM EGTA pH 8, 50 mM HEPES pH 7,6).
Cell extract was diluted in 1 mL Chromatin incubation buffer (0,75 % SDS, 5 % Triton X-100, 0,75 M NaCl, 5 mM EDTA pH 8, 2,5 mM EGTA pH 8, 100 mM HEPES pH 7,6) and 1 x complete protease inhibitor cocktail (PIC) (# 1697498, Roche, Mannheim) and sonicated according to the manufacturer`s protocol using the Diagenode Bioruptor (Diagenode, Liège, Belgium). One hundred µL chromatin was saved as input. diluted 1:1000 in blocking buffer. Peroxidase-conjugated anti-rabbit IgG (A0545, Sigma) was used as a secondary antibody at a dilution of 1:1000. Bound antibody was detected using the ECL kit (Amersham) and was visualised on X-Ray film.
In preparation of immunoprecipitation protein
Statistics
Statistical analysis was performed using the Student`s T-test. A value p<0.05 was considered significant.
Results
Induction of IL-10 mRNA and protein by Methyl-Prednisolone
Human B cells are a ready source of IL-10. MP treatment of purified CD19+ B cells from human peripheral blood led to a 3-fold induction of IL-10 mRNA (n= 6, p< 0.05, see Figure 1A ). In order to study the molecular mechanisms involved in the induction of this gene in B cells we turned to a model B cell line.
The RPMI 82226.1 B cell line has proven a useful model in previous studies on the expression of IL-10 when using stimuli like LPS and Interferon alpha (Benkhart et al., 2000; Ziegler-Heitbrock et al., 1994; Ziegler-Heitbrock et al., 2003) .
Methyl-Prednisolone readily induced IL-10 protein in these cells as shown in Figure 1B . Overnight treatment with the glucocorticoid at 10 -6 M led to a 23-fold increase of protein in the culture supernatant as detected by ELISA (Fig 1B) .
When analysing the mRNA expression we tested different concentrations of MP and found the highest induction (17-fold) when treating the cells for 4 h with 10 -6
M of the glucocorticoid. The response was lower at 10E -7 M and still was evident as a 5-fold increase at 10E -8 M (Fig 1C) . Using a dose of 10 -6 M a time course study demonstrated maximum levels of IL-10 transcripts at 2 and 4 hours with the levels returning to background at 24 h (Fig 1D) . These data show that MP can induce IL-10 in the model cell line in a dose and time dependent manner.
Induction of the IL-10 promoter by Methyl-Prednisolone
While the induction of IL-10 by MP has been known for some time, the molecular mechanisms involved thus far remained elusive. For the study of these mechanisms we transfected the RPMI 8226.1 cells with a luciferase reporter plasmid driven by the -1044 IL-10 promoter. Transfected cells were stimulated with MP for 6 h and luciferase activity was determined in cell lysates with reference to a control plasmid encoding Renilla luciferase. In these studies MP at 10 -6 M led to a 18-fold induction of the promoter, while at 10 -7 M it was 11-fold and at 10 -8 M there was still a 2-fold induction (Fig 2) . When comparing promoter activity and induction of IL-10 mRNA levels (Fig 1C) , then a very similar degree of stimulation with a similar dose response is seen suggesting that the regulation of IL-10 mRNA expression by glucocorticoids is mainly transcriptional.
The schematic drawing of the promoter construct in the upper part of Figure 2 indicates the location of transcription factor motifs for Sp1, IRF and STAT that have been described in previous reports. In addition a potential GRE motif can be identified at -316 ( Figure 2 ). In order to ascertain whether this motif is necessary for the induction of the IL-10 gene we turned to shorter constructs lacking this site.
When analysing a -195 IL-10 promoter luciferase reporter gene construct we noted an 8,8-fold induction of the wt construct by MP at 10 -6 M (Figure 3 ), suggesting that the potential GRE motif is dispensable for induction by glucocorticoids.
Role of the -120 STAT-motif in induction of the IL-10 promoter by MethylPrednisolone
We then studied the role of the IRF and STAT sites within this short fragment by transfecting constructs with specific mutants of these sites. The IRF mutant (IRFm) construct did show an unaltered activity as compared to wt, but surprisingly the STAT mutant (STATm) showed strongly reduced activity and the same was found for a construct with mutation of both sites (Figure 3 ). These data indicate that the STAT motif may be crucially involved in the glucocorticoid induction of the human IL-10 gene. Since there still was some induction of the IL-10 gene even in the STAT mutant, we asked whether there might be another element within this -150 fragment, that may be involved in the induction. For this we employed a linker scanning series as described previously, which stepwise replaces promoter sequences with an inert decameric sequence (Benkhart et al., 2000) . When cells were transfected with these constructs and treated with MP, a significant decrease in glucocorticoid inducibility was only observed for the mutation at -120 bp, i.e. of the STAT motif (LS4 in Figure 4 ). Hence, no additional elements involved in glucocorticoid mediated IL-10 promoter induction were identified within this -150 fragment of the promoter.
We next asked whether Methyl-Prednisolone would induce a promoter construct carrying a multimer of the STAT-motif. A construct with a trimer of the IL-10 promoter STAT-motif in front of the luciferase reporter gene did, in fact, show a robust induction by MP, which was in average 28,8-fold ( Figure 5 ). This demonstrates that glucocorticods can induce a strong transactivation through a STAT site.
Role of STAT3 in the induction of the IL-10 gene by Methyl-Prednisolone
Since We therefore performed gelshift analysis using a radiolabelled double-stranded oligonucleotides encompassing the IL-10 promoter STAT-motif. As shown in Figure 7A , LPS stimulation of the cells will induce a DNA-protein-complex with a maximum signal at 4 h, as demonstrated previously (Benkhart et al., 2000) . MP treatment of the cells will induce no binding protein at 1h but there is a strong signal at 2 h, which decreases at 4 h. Supershift analysis of this binding protein was performed at the 2 h time point and demonstrated a complete shift of the band by the anti-STAT3 antibody but not by control antibody ( Figure 7B ). These data support a crucial involvement of STAT3 in glucocorticoid-mediated induction of IL-10.
Methyl-Prednisolone induces binding of STAT3 to the IL-10 promoter in intact cells
In 
Discussion
IL-10 is produced by B cells and this cytokine has been shown to act in an autocrine fashion in proliferation and differentiation of these cells (Masood et al., 1995; O'Garra et al., 1990; Rousset et al., 1992) but also in induction of apoptosis of leukemic B cells (Fluckiger et al., 1994) .
IL-10 can be induced in B cells by engagement of the B cell receptor (Fillatreau et al., 2002) , via CD40 ligation (Mauri et al., 2003) , Interferon-alpha stimulation When considering the possible mechanism leading to involvement of STAT3 in GC induction of IL-10 gene expression the question is, whether there is any role for the GCR. In fact, we could demonstrate a complete blockade of IL-10 mRNA production and promoter activity using the steroid receptor blocker RU-486 (data not shown). Based on this one might consider the possibility that the GCR directly interacts with the STAT3.
The interaction of glucocorticoids with STAT3 have been described earlier for the regulation of genes like fibrinogen and alpha 2 macroglobulin (Duan and Simpson-Haidaris, 2006; Lerner et al., 2003; Takeda et al., 1998) . In all these cases GCs do have little activity on their own but they operate synergistically with IL-6 induced STAT3. This synergistic action is mediated by interaction of the GCR protein with the STAT3 protein (Lerner et al., 2003) . This is clearly different from the present system where GC alone will induce substantial STAT3 and this will bind and transactivate the IL-10 promoter leading to gene expression without any apparent co-stimulus.
The question then is: how do GCs increase STAT3 binding to the IL-10 promoter in intact cells? One possibility is that binding of the GCR to STAT3 will stabilize its DNA binding and retention in the nucleus. This would imply that STAT3
shuttling between cytoplasm and nucleus is trapped by attachment to the GCR. To this end we failed to demonstrate GCR binding to the proximal IL-10 promoter by
ChIP, but these preliminary results may be due to inappropriate conditions and reagents for detection of this transcription factor.
Another possibility is that GCR action leads to enhanced serine-phosphorylation As discussed above GC can also induce IL-10 in monocytes (Mozo et al., 2004) , in macrophages (Frankenberger et al., 2005) and in T cells (Barrat et al., 2002; Richards et al., 2000) .
The mode of action of GC in inducing IL-10 in these cells is still unclear but the current data on the molecular mechanism in B cells may provide a paradigm for the way IL-10 is induced by GC in other leukocytes. The cartoon at the top shows schematically the IRF and the STAT site with X denoting their mutation as described (Benkhart et al., 2000) . 
